Corvus Pharmaceuticals, Inc. (CRVS) Stock
CRVS has an Alpha Score of 24 out of 100 (poor), computed on Nov 8, 2026 from 2 of 4 sub-scores. 4 of the hedge funds AlphaScala tracks reported CRVS in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Millennium Management's at $15.66M.
What is CRVS's Alpha Score?
How it works →Alpha Score of 24 reflects poor overall profile with poor momentum, moderate quality. Based on 2 of 4 signals – score is capped at 75 until remaining data ingests.
Computed from 2 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 8, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which hedge funds own CRVS?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Millennium Management Israel Englander | 1.05M | $15.66M | +21% |
| Citadel Ken Griffin | 398K | $5.95M | -10% |
| D.E. Shaw David Shaw | 133K | $1.99M | NEW |
| Marshall Wace | 100K | $1.50M | -82% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →What are CRVS's key statistics?
Key statistics as of Nov 8, 2026
CRVS price chart
Powered by TradingViewWhat does Corvus Pharmaceuticals, Inc. do?
Corvus Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing investigational therapies that modulate immune pathways for cancer and immune-mediated diseases. Its primary emphasis is on ITK inhibition through its lead product candidate, soquelitinib, an oral small molecule designed to selectively target interleukin-2-inducible T cell kinase, influencing T cell differentiation and function. This approach aims to address conditions such as peripheral T cell lymphomas, atopic dermatitis, autoimmune lymphoproliferative syndrome, and other inflammatory disorders by promoting Th1 immune responses while suppressing Th2 and Th17 pathways. The company also advances other immune modulators, including ciforadenant, an A2A receptor antagonist for metastatic renal cell cancer, and mupadolimab, a monoclonal antibody for non-small cell lung cancer, often in combination with checkpoint inhibitors. Founded in 2014 and headquartered in South San Francisco, California, Corvus Pharmaceuticals Inc. operates through clinical trials, strategic collaborations like those with Angel Pharmaceuticals for greater China, and preclinical programs targeting adenosine pathways and CXCR2. It plays a specialized role in immuno-oncology and immunology within the biopharmaceutical sector.